Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний
- Название:Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний
- Автор:
- Жанр:
- Издательство:Эксмо
- Год:2021
- Город:Москва
- ISBN:978-5-04-155994-6
- Рейтинг:
- Избранное:Добавить в избранное
-
Отзывы:
-
Ваша оценка:
Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний краткое содержание
Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний - читать онлайн бесплатно ознакомительный отрывок
Интервал:
Закладка:
18. Hogue C. Trump administration delays bans of toxic solvents. Chemical & Engineering News. December 20, 2017. https://cen.acs.org/articles/95/ web/2017/12/Trump-administration-delays-bans-toxic.html. Accessed March 28, 2019.
19. Barringer F. E.P.A. charts risks of a ubiquitous chemical. New York Times. September 30, 2011; Vettel P. Worried about decaf coffee? Fears are groundless. Chicago Tribune. May 19, 1985. www.chicagotribune. com/news/ct-xpm-1985-05-19-8502010068-story.html. Accessed July 19, 2019.
20. What is Superfund? US Environmental Protection Agency. www.epa. gov/superfund/what-superfund. Updated November 30, 2018. Accessed March 28, 2019.
21. Record of decision: Modock Road Springs/DLS Sand and Gravel, Inc. Site, Town of Victor, Ontario County, New York, Site Number 8-35-013. New York State Department of Environmental Conservation. January 2010. www.dec.ny.gov/docs/remediation_hudson_pdf/ 835013rod.pdf. Accessed March 29, 2019.
22. Trichloroethylene. US Environmental Protection Agency. April 1992. www.epa.gov/sites/ production/files/2016-09/documents/ trichloroethylene.pdf. Updated January 2000. Accessed March 28, 2019.
23. Trichloroethylene (TCE) general fact sheet. In Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services. www.gsa.gov/cdnstatic/ Trichloroethylene_%28TCE%29_ NEW_general_fact_sheet.pdf. Accessed March 29, 2019.
24. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018; Integrated Risk Information System: trichloroethylene. US Environmental Protection Agency. https:// cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=199. Updated July 28, 2017. Accessed March 28, 2019.
25. Watts M. Paraquat. Pesticide Action Network Asia & the Pacific. February 2011. www.panna.org/sites/default/files/Paraquat%20 monograph%20final%202011-1.pdf. Accessed June 28, 2019; China about to ban all sales and use of paraquat by 2020 [пресс-релиз]. CCM Data & Business Intelligence, July 31, 2017. www.cnchemicals. com/Press/89866-China%20 about%20to%20ban%20all%20sales%20 and%20use%20of%20paraquat%20by%202020.html. Accessed June 28, 2019.
26. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872.
27. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/ usage /maps/show_map.php? year=2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.
28. Jenkins D. Court grants EPA new hearing on pesticide ban. Capital Press. February 12, 2019; O’Neill E. Will an appeals court make the EPA ban a pesticide linked to serious health risks? The Salt. February 26, 2019. www.npr.org/sections/thesalt/2019/02/26/698227414/will-an-appeals-court-make-the-epa-ban-a-pesticide-linked-to-serious-health-risk. Accessed June 28, 2019.
29. Friedman L. E.P.A. won’t ban chlorpyrifos, pesticide tied to children’s health problems. New York Times. July 18, 2019. www. nytimes.com/2019/07/18/climate/epa-chlorpyrifos-pesticide-ban. html?smid=nytcore-ios-share.
30. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics. 1998;62(3):676–689; Danaei G, Vander Hoorn S, Lopez AD, Murray CJL, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. The Lancet. 2005;366(9499):1784–1793; Brody JG, Moysich KB, Humblet O, Attfield KR, Beehler GP, Rudel RA. Environmental pollutants and breast cancer. Cancer. 2007; 109(S12):2667–2711; McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer – epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624–628.
31. Hofman A, Stricker BH, Ikram MA, Koudstaal PJ, Darweesh SKL. Trends in the incidence of Parkinson disease in the general population: the Rotterdam Study. American Journal of Epidemiology. 2016;183(11):1018–1026.
32. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306.
33. Okun MS. Parkinson’s Treatment: 10 Secrets to a Happier Life (CreateSpace, 2013)/«10 секретов надежды и счастливой жизни с болезнью Паркинсона» Майкл Окун (фрагмент книги опубликован в интернете); Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurology . 2012;11(2):140–149; Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE Trial. Annals of Neurology. 2009;65(5): 586–595; Okun MS. Ask the Doctor About Parkinson’s Disease. 1st ed. Demos Health; 2009. Okun MS. 10 Breakthrough Therapies for Parkinsons Disease: English Edition. 1st ed. Books4Patients; 2015.
34. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson’s disease: a review of two interconnected, episodic phenomena. Movement Disorders. 2004; 19(8):871–884; Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson’s disease. Journal of Neurology. 2001;248(11):950–958; Nijkrake MJ, Keus SHJ, Overeem S, et al. The ParkinsonNet concept: development, implementation and initial experience. Movement Disorders. 2010;25(7):823–829; Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands. Health Affairs. 2017;36:1987–1996.
35. Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology . 2017;89(11):1152–1161; Dorsey ER, Venkataraman V, Grana MJ, et al. Randomized controlled clinical trial of “virtual house calls” for Parkinson disease. JAMA Neurology. 2013;70(5):565–570.
Глава 1: Шестеро лондонцев
1. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.
2. Morris AD, Rose FC. James Parkinson: His Life and Times . Boston: Birkhauser; 1989.
3. Blake, W The Poetical Works of William Blake, ed. by John Sampson. London, New York: Oxford University Press, 1908; Bartleby.com, 2011. www.bartleby.com/235/284.html.
4. Ritchie H. What the history of London’s air pollution can tell us about the future of today’s growing megacities. Our World in Data. June 20, 2017. https://ourworldindata.org/london-air-pollution. Accessed December 12, 2018.
5. Там же.
6. Morris AD, Rose FC. James Parkinson: His Life and Times. Birkhauser; 1989.
7. Там же.
8. Там же.
9. Там же.
10. Zhang Z, Dong Z, Roman GC. Early descriptions of Parkinson disease in ancient China. Archives of Neurology. 2006;63(5):782–784; Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Movement Disorders. 2013;28(5):566–568; Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310; Lees AJ. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson’s 250th birthday. Movement Disorders . 2007;22(S17):S327-S334.
11. Zhang Z, Dong Z, Roman GC. Early descriptions of Parkinson disease in ancient China. Archives of Neurology . 2006;63(5):782–784; Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Movement Disorders. 2013;28(5):566–568.
12. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310.
13. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862.
14. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310; Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862.
15. Osler W, Sir. The Principles and Practice of Medicine. New York: D. Appleton and Company; 1892.
16. Carlsson A. Nobel lecture: a half-century of neurotransmitter research: impact on neurology and psychiatry. Bioscience Reports . 2001;21(6):691–710.
17 Там же; Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
18. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
19. Carlsson A. Nobel lecture: a half-century of neurotransmitter research: impact on neurology and psychiatry. Bioscience Reports. 2001;21(6):691–710.
20. Hagerty JR. Arvid Carlsson, snubbed at University in Sweden, found a path to Nobel Prize in medicine. Wall Street Journal. July 13, 2018.
21. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences. 1973;20(4):415–455.
22. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
23. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research. 2004;318(1): 121–134; Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). Journal of Neurology . 2002;249(3):iii1-iii5.
24. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology . 2006;5(3):235–245; Park A, Stacy M. Non-motor symptoms in Parkinson’s disease. Journal of Neurology . 2009;256(3):293–298.
25. Schrag A. Quality of life and depression in Parkinson’s disease. Journal of the Neurological Sciences. 2006;248(1):151–157; Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Movement Disorders . 2001;16(3):507–510; Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders . 2011;26(3):399–406.
Читать дальшеИнтервал:
Закладка:
